CNAT - Conatus Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
32,890
33,586
35,377
799
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
36,498
41,368
43,220
20,294
16,298
Selling General and Administrative
10,833
10,495
9,707
10,337
7,833
Total Operating Expenses
47,331
51,863
52,927
30,631
24,131
Operating Income or Loss
-14,441
-18,277
-17,550
-29,832
-24,131
Interest Expense
324
696
662
70
70
Total Other Income/Expenses Net
10
267
154
98
-16
Income Before Tax
-13,898
-18,010
-17,396
-29,733
-24,149
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-13,898
-18,010
-17,396
-29,733
-24,149
Net Income
-13,898
-18,010
-17,396
-29,733
-24,149
Net Income available to common shareholders
-13,898
-18,010
-17,396
-29,733
-24,149
Reported EPS
Basic
-
-0.59
-0.61
-1.31
-1.30
Diluted
-
-0.59
-0.61
-1.31
-1.30
Weighted average shares outstanding
Basic
-
30,370
28,587
22,650
18,618
Diluted
-
30,370
28,587
22,650
18,618
EBITDA
-
-18,277
-17,550
-29,832
-24,079